Correlation between serum cyclophilin A and acute ST-segment elevation myocardial infarction and its predictive value

Area of Science:

• Cardiology
• Biomarker Discovery
• Molecular Medicine

Background:

• Acute ST-segment elevation myocardial infarction (STEMI) is a critical cardiovascular emergency requiring prompt diagnosis and treatment.
• Identifying novel biomarkers is crucial for improving patient outcomes in STEMI.
• Serum cyclophilin A (CyPA) has emerged as a potential factor in cardiovascular disease development.

Purpose of the Study:

• To investigate the association between serum cyclophilin A (CyPA) levels and acute ST-segment elevation myocardial infarction (STEMI).
• To evaluate the potential of CyPA as a predictive biomarker for STEMI risk.
• To assess the diagnostic and prognostic value of CyPA in acute STEMI patients.

Main Methods:

• A case-control study involving 264 acute STEMI patients and 264 healthy controls.
• Multivariate logistic regression analysis to determine the association between CyPA and STEMI.
• Receiver operating characteristic (ROC) curve analysis, reclassification analysis, calibration curves, and decision curve analysis (DCA) to assess predictive value.

Main Results:

• Serum CyPA levels were significantly elevated in STEMI patients compared to controls (P < 0.001).
• CyPA was identified as an independent risk factor for acute STEMI (OR = 1.15, 95% CI: 1.09-1.23).
• ROC analysis demonstrated a high diagnostic accuracy for CyPA (AUC = 0.994), with significant improvements in risk prediction models (NRI = 0.0682, IDI = 0.0438).

Conclusions:

• Serum cyclophilin A levels are strongly associated with the occurrence of acute STEMI.
• CyPA demonstrates significant potential as a novel and reliable biomarker for the early detection and risk stratification of acute STEMI.
• Further research is warranted to elucidate the precise role of CyPA in STEMI pathogenesis.